Bevacizumab (brand name avastin) for metastatic colorectal cancer (standard of care in the Netherlands, approved by the FDA and EMA and recommended by the consensus guidelines of ESMO https://www.esmo.org/guidelines/guidelines-by-topic/esmo-cli...) and is a well known example. See the response of parliament to a petition to change it now that the patent has expired. NHS will still not fund it and cites cost as an important factor https://petition.parliament.uk/petitions/616742?reveal_respo... . I would note that since funds are limited, any system needs some kind of cost-benefit analysis for drugs to ensure affordability of care. Making this cost-benefit analysis central, transparant, and explicit is probably the best way to do it.